Journal ArticleDOI
Coronary heart disease risk: Low-density lipoprotein and beyond
TLDR
In this article , the authors summarize the body of evidence implicating each of these risk factors in residual coronary heart disease risk, including systemic inflammation, diabetes mellitus, high-density lipoprotein, plasma triglycerides (TG), residual lipoproteins (RLP), and vascular endothelial dysfunction (ED).About:
This article is published in Trends in Cardiovascular Medicine.The article was published on 2022-05-01. It has received 22 citations till now. The article focuses on the topics: Residual risk & Medicine.read more
Citations
More filters
Journal ArticleDOI
Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome
Hui Li,Yuan-Lin Guo,Zhenggang Zhu,Na-Qiong Wu,Ying Gao,Rui-Xia Xu,Qiang Dong,Jie Qian,Kefei Dou,Jian-Jun Li +9 more
TL;DR: In this paper , the combined effect of residual cardiovascular risk (RCVR) factors on the prognosis of statin-treated patients with chronic coronary syndrome (CCS), including LDL-C < 2.6 mmol/L, was investigated.
Journal ArticleDOI
Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome
Hui Li,Yuan-Lin Guo,Zhenggang Zhu,Na-Qiong Wu,Ying Gao,Rui-Xia Xu,Qiang Dong,Jie Qian,Kefei Dou,Jian-Jun Li +9 more
TL;DR: In this paper , the combined effect of residual cardiovascular risk (RCVR) factors on the prognosis of statin-treated patients with chronic coronary syndrome (CCS), including LDL-C < 2.6 mmol/L, was investigated.
Journal ArticleDOI
F2RL3 Methylation in the Peripheral Blood as a Potential Marker for the Detection of Coronary Heart Disease: A Case-Control Study
TL;DR: Blood-based F2RL3 methylation is proposed as a potential biomarker for CHD, especially for people with older age or with the status of MI, and the combination of F2 RL3methylation and conventional risk factors might be an approach to evaluate CHD at early stage.
Journal ArticleDOI
Association between heart rate and cardiovascular death in patients with coronary heart disease: A NHANES‐based cohort study
TL;DR: In this paper , the association between the specific range of heart rate and cardiovascular death in coronary heart disease (CHD) patients was assessed and the results showed that CHD patients were more likely to die from heart failure.
Journal ArticleDOI
Circulating brain‐derived neurotrophic factor dysregulation and its linkage with lipid level, stenosis degree, and inflammatory cytokines in coronary heart disease
TL;DR: The expression of BDNF and its relationship with stenosis, inflammation, and adhesion molecules in CHD patients is explored in patients with confirmed history of coronary heart disease.
References
More filters
Journal ArticleDOI
Inflammation, Atherosclerosis, and Coronary Artery Disease
TL;DR: The evidence is recounted that atherosclerosis, the main cause of CAD, is an inflammatory disease in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial tree.
Journal Article
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
R C Turner,Rury R. Holman,Irene M Stratton,Carole A. Cull,David R Matthews,Susan E. Manley,V Frighi,D Wright,Andrew Neil,E M Kohner,H McElroy,C Fox,D R Hadden,Grp Ukpds. +13 more
TL;DR: Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients.
Journal ArticleDOI
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Frank M. Sacks,Marc A. Pfeffer,Lemuel A. Moyé,Jean L. Rouleau,John D. Rutherford,Thomas G. Cole,Lisa E. Brown,J. W. Warnica,J. M. O. Arnold,Chuan Chuan C Wun,Barry R. Davis,Eugene Braunwald +11 more
TL;DR: It is demonstrated that the benefit of cholesterol-lowering therapy extends to the majority of patients with coronary disease who have average cholesterol levels and was also greater in patients with higher pretreatment levels of LDL cholesterol.
Journal ArticleDOI
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
J. Shepherd,Stuart M. Cobbe,Ian Ford,C. G. Isles,AR Lorimer,Peter W. Macfarlane,J. H. Mckillop,Christopher J. Packard +7 more
TL;DR: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.
Journal ArticleDOI
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein,Michael Miller,Robert P. Byington,David C. Goff,J. Thomas Bigger,John B. Buse,William C. Cushman,Saul Genuth,Faramarz Ismail-Beigi,Faramarz Ismail-Beigi,Richard H. Grimm,Jeffrey L. Probstfield,Denise G. Simons-Morton,William T. Friedewald +13 more
TL;DR: In this paper, the authors investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.